PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study

INTRODUCTION: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function. METHODS: We examined the association of genetic variants in PCSK9 with continuous measures of cogni...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyall, Donald M., Ward, Joey, Banach, Maciej, Smith, George Davey, Gill, Jason G., Pell, Jill P., Holmes, Michael V., Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811317/
https://www.ncbi.nlm.nih.gov/pubmed/33488877
http://dx.doi.org/10.5114/aoms/127226
Descripción
Sumario:INTRODUCTION: PCSK9 inhibitors lower low-density lipoprotein (LDL) cholesterol and are efficacious at reducing vascular disease, however questions remain about potential effects on cognitive function. METHODS: We examined the association of genetic variants in PCSK9 with continuous measures of cognitive ability in UK Biobank. Six independent polymorphisms in PCSK9 were used in up to 337,348 individuals. RESULTS: The PCSK9 allele score was associated with a lower risk of CHD, and weakly with worse log reaction time. CONCLUSIONS: We are unable to rule out meaningful associations of PCSK9 genetic variants with cognition, emphasising the potential need for continued pharmacovigilance for patients currently treated with PCSK9 inhibitors.

Ejemplares similares